RJx-01 Phase 2 Trial Targets Muscle Loss With Multi-Pathway Drug Approach
Rejuvenate Biomed completes enrollment of 198 patients testing RJx-01 for COPD-induced sarcopenia, with results due late 2026.
Summary
Rejuvenate Biomed has finished enrolling 198 participants across Europe and the UK in a Phase 2 trial of RJx-01, a drug designed to fight muscle loss caused by COPD. Sarcopenia — the progressive loss of muscle mass and strength — affects millions of older adults and currently has no approved drug treatments. Unlike previous experimental approaches that targeted a single mechanism, RJx-01 simultaneously addresses mitochondrial dysfunction, inflammation, and fibrosis. Early Phase 1 data showed improvements in both biological markers and physical muscle performance. Topline results are expected by end of 2026, and if successful, this trial could open a regulatory pathway that bridges aging biology with mainstream medicine.
Detailed Summary
Sarcopenia — the age-related loss of muscle mass and strength — has long been recognized as a major driver of frailty, hospitalization, and lost independence in older adults, yet no approved pharmacological treatment exists. Rejuvenate Biomed, a Belgium-based biotech, is working to change that with RJx-01, a multi-pathway therapeutic now in Phase 2 clinical trials targeting COPD-induced sarcopenia.
The company has completed enrollment of 198 participants across European and UK trial sites, with topline results anticipated before the end of 2026. The scale and geographic reach of the trial mark a meaningful step forward for a field that has historically struggled to translate promising biology into clinical outcomes.
What distinguishes RJx-01 from previous attempts is its simultaneous targeting of multiple mechanisms known to drive muscle deterioration — mitochondrial dysfunction, chronic inflammation, and fibrosis. Single-axis approaches have repeatedly failed to deliver meaningful functional benefit in sarcopenia, making this multi-pathway strategy a notable departure from the norm.
Early human data from a Phase 1 immobilization study (14-day leg casting) showed that RJx-01 influenced muscle transcriptomics in ways reflecting mitochondrial health, inflammation reduction, collagen deposition, and neuromuscular signaling — and these effects were accompanied by measurable improvements in muscle strength and performance. CEO Dr. Ann Beliën noted that the mechanisms identified are relevant not only to immobilization-induced sarcopenia but to age-related muscle decline more broadly.
The trial carries significance beyond COPD: sarcopenia is increasingly viewed in geroscience as a genuine endpoint for aging biology, potentially offering one of the first viable regulatory bridges between the science of aging and mainstream medicine. Investors, clinicians, and longevity researchers should watch the late-2026 readout closely, while noting that Phase 2 results remain preliminary and regulatory approval is still a considerable distance away.
Key Findings
- RJx-01 simultaneously targets mitochondrial dysfunction, inflammation, and fibrosis — a multi-pathway approach unique in sarcopenia treatment.
- 198 participants enrolled across Europe and UK; Phase 2 topline results expected by end of 2026.
- No pharmacological treatment for sarcopenia is currently approved anywhere, making this trial a significant regulatory milestone.
- Phase 1 data showed functional muscle strength improvements alongside positive biological marker changes in healthy subjects.
- Sarcopenia may become a key regulatory bridge allowing aging-biology therapeutics to enter mainstream clinical medicine.
Methodology
This is a news report from Longevity.Technology, a specialist industry publication covering aging and longevity biotech. The article draws on a direct interview with Rejuvenate Biomed's CEO and references Phase 1 and Phase 2 trial data. No peer-reviewed publication of results is cited; evidence basis is company-disclosed clinical data and executive commentary.
Study Limitations
Results reported are from company communications and a CEO interview, not peer-reviewed publications. Phase 2 data has not yet been released; topline outcomes are expected late 2026 and may differ from Phase 1 signals. The trial is specific to COPD-induced sarcopenia, and generalizability to age-related sarcopenia remains to be demonstrated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.